Amy Erbe-Gurel, PhD, assistant professor, Division of Hematology, Oncology, Transplant, and Cellular Therapy, and co-investigator Josh Lang, MD, MS, professor, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, were awarded a one-year $25,000 award from Cancer Center Support Grant Program Pilot through the UW Carbone Cancer Center for their study, “Development of bispecific antibody, anti-GD2 x anti-CD40, to target the tumor microenvironment for treatment of high-risk neuroblastoma.” This study will develop a novel bispecific antibody, aGD2×aCD40, designed to treat neuroblastoma by binding GD2 on tumor cells and CD40 on immune cells. The drug activates immune cells only when in direct contact with cancer, aiming to boost anti-tumor activity while minimizing harmful side effects.